JP2021509679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021509679A5 JP2021509679A5 JP2020537571A JP2020537571A JP2021509679A5 JP 2021509679 A5 JP2021509679 A5 JP 2021509679A5 JP 2020537571 A JP2020537571 A JP 2020537571A JP 2020537571 A JP2020537571 A JP 2020537571A JP 2021509679 A5 JP2021509679 A5 JP 2021509679A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614956P | 2018-01-08 | 2018-01-08 | |
| US62/614,956 | 2018-01-08 | ||
| US201862699345P | 2018-07-17 | 2018-07-17 | |
| US62/699,345 | 2018-07-17 | ||
| PCT/US2019/012228 WO2019136185A1 (en) | 2018-01-08 | 2019-01-03 | Compositions and methods of treating cancer with glycomimetic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509679A JP2021509679A (ja) | 2021-04-01 |
| JP2021509679A5 true JP2021509679A5 (https=) | 2022-01-04 |
| JP7390294B2 JP7390294B2 (ja) | 2023-12-01 |
Family
ID=67143977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537571A Active JP7390294B2 (ja) | 2018-01-08 | 2019-01-03 | 糖鎖模倣ペプチドを用いて癌を処置する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11376307B2 (https=) |
| EP (1) | EP3737365A4 (https=) |
| JP (1) | JP7390294B2 (https=) |
| AU (1) | AU2019205279A1 (https=) |
| CA (1) | CA3086751A1 (https=) |
| WO (1) | WO2019136185A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019205279A1 (en) * | 2018-01-08 | 2020-07-30 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| JP2023536815A (ja) * | 2020-07-28 | 2023-08-30 | スサヴィオン バイオサイエンシーズ インコーポレイテッド | 好中球駆動性炎症性病変の治療方法 |
| US20250222064A1 (en) * | 2022-03-24 | 2025-07-10 | Wild Boar Biosciences, Llc | Method of treatment of neutrophil-driven inflammatory pathologies |
| US20230364255A1 (en) * | 2020-08-18 | 2023-11-16 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2272947B1 (en) | 2000-09-05 | 2016-08-10 | Biosight Ltd | Peptide conjugated anti-cancer prodrugs |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| CA2566647A1 (en) * | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
| EP2497783A3 (en) * | 2007-09-26 | 2013-04-17 | U3 Pharma GmbH | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| CN103328496A (zh) | 2010-10-25 | 2013-09-25 | 中央研究院 | 癌靶向肽及其于癌症治疗与诊断的应用 |
| WO2013096829A2 (en) | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| US20150079071A1 (en) * | 2012-11-30 | 2015-03-19 | The Regents Of The University Of California | Non-catalytic domain targets in matrix metalloprotease proteins for cancer therapies |
| GB201300706D0 (en) * | 2013-01-15 | 2013-02-27 | Cancer Rec Tech Ltd | Antibody |
| US10617755B2 (en) * | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| WO2015143091A1 (en) * | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| WO2016033602A1 (en) * | 2014-08-30 | 2016-03-03 | Susavion Biosciences, Inc. | Activation of adaptive immune processes for the treatment of cancers and infectious diseases |
| WO2016044716A1 (en) * | 2014-09-19 | 2016-03-24 | The American University In Cairo | Nanoparticle-based combinatorial therapy |
| JP6649953B2 (ja) | 2014-12-19 | 2020-02-19 | スサヴィオン バイオサイエンシーズ インコーポレイテッド | 免疫療法による治療および組成物 |
| JP6740250B2 (ja) * | 2015-04-27 | 2020-08-12 | スサヴィオン バイオサイエンシーズ インコーポレイテッド | がんおよび持続性ウイルス感染を処置するための組成物および方法 |
| EP3294887A1 (en) * | 2015-05-14 | 2018-03-21 | CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Mirna compositions for the treatment of mature b-cell neoplasms |
| EP3371212B1 (en) * | 2015-11-06 | 2023-10-11 | The Board of Trustees of the University of Illinois | Peptides and method for treatment of cardiac arrest |
| FI3439662T3 (fi) * | 2016-04-04 | 2024-09-04 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita |
| AU2017277288B2 (en) * | 2016-06-09 | 2024-05-16 | Omeros Corporation | Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer |
| AU2019205279A1 (en) * | 2018-01-08 | 2020-07-30 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
-
2019
- 2019-01-03 AU AU2019205279A patent/AU2019205279A1/en not_active Abandoned
- 2019-01-03 US US16/960,267 patent/US11376307B2/en active Active
- 2019-01-03 CA CA3086751A patent/CA3086751A1/en active Pending
- 2019-01-03 JP JP2020537571A patent/JP7390294B2/ja active Active
- 2019-01-03 WO PCT/US2019/012228 patent/WO2019136185A1/en not_active Ceased
- 2019-01-03 EP EP19735760.1A patent/EP3737365A4/en not_active Withdrawn
-
2022
- 2022-06-27 US US17/850,976 patent/US20220331394A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sandhiya et al. | The dawn of hedgehog inhibitors: Vismodegib | |
| JP2026027329A (ja) | ネクチン－４に特異的な二環コンジュゲート及びその使用 | |
| JP2021509679A5 (https=) | ||
| KR20170117113A (ko) | 면역 관문 저해제와 조합한 플리나불린의 용도 | |
| Aguiar Jr et al. | Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
| TW201107327A (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| Ma et al. | The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation | |
| TW202228724A (zh) | 以反轉錄酶抑制劑治療癌症之方法 | |
| EP3735267A1 (en) | Methods for treating colorectal and metastatic colorectal cancers | |
| JP2022508935A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| CN119816313A (zh) | 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法 | |
| Qin et al. | CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies | |
| CN112584842A (zh) | 使用锌剂的肿瘤治疗 | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| Takashima et al. | Standard first-line chemotherapy for metastatic gastric cancer in Japan has met the global standard: evidence from recent phase III trials | |
| EP4309658A1 (en) | Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof | |
| US20230116137A1 (en) | Methods for treating colorectal and metastatic colorectal cancers | |
| KR20240023592A (ko) | 삼중 병용 요법 | |
| Yi et al. | Immunotherapy of triple-negative breast cancer | |
| CN114225023B (zh) | 抗csf-1r抗体联合抗pd-l1抗体的应用 | |
| TW202304512A (zh) | 雙特異性t細胞銜接體之給藥 | |
| CA3250299A1 (en) | CANCER TREATMENT | |
| KR20230028321A (ko) | 암의 치료 |